BAY 43-9006 regulatory update

BAYG said the EC granted Orphan Drug designation for BAY 43-9006 to treat renal cell carcinoma (RCC). BAY 43-9006, an inhibitor of Raf kinase and VEGF receptor, is in Phase III testing for metastatic ...